Treatment of relapsed multiple myeloma: New combinations, new generations, new targets

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale, AZ, summarises recently approved treatment options for patients with relapsed multiple myeloma, including proteasome inhibitors, carfilzomib and ixazomib; histone deacetylase (HDAC) inhibitor, panobinostat; and monoclonal antibodies, CS1-targeting elotuzumab and CD38-targeting daratumumab.

Share this video